CAR-T cells beyond CD19, UnCAR-Ted territory

Mark B Leick; Marcela V Maus

doi:10.1002/ajh.25398

CAR-T cells beyond CD19, UnCAR-Ted territory

Am J Hematol. 2019 May;94(S1):S34-S41. doi: 10.1002/ajh.25398. Epub 2019 Jan 23.

Authors

Mark B Leick^{1

2}, Marcela V Maus^{1

2}

Affiliations

¹ Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.

PMID: 30632631
DOI: 10.1002/ajh.25398

Abstract

CAR-T cells have made dramatic inroads in targeting CD19-positive B-cell malignancies. This review focuses on application of CAR-T cells in hematologic malignancies beyond targeting CD19, with specific attention to Hodgkin's lymphoma and acute myeloid leukemia.

Publication types

Review

MeSH terms

Hematologic Neoplasms / therapy*
Hodgkin Disease / therapy
Humans
Immunotherapy, Adoptive / methods*
Leukemia, Myeloid, Acute / therapy
Receptors, Antigen, T-Cell / immunology
Receptors, Antigen, T-Cell / therapeutic use*

Substances

Receptors, Antigen, T-Cell